Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

<p><strong>Background & Aims</strong> Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel disea...

書誌詳細
主要な著者:	Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C
フォーマット:	Journal article
言語:	English
出版事項:	Elsevier 2019

類似資料

International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease
著者:: Williamson, K, 等
出版事項: (2018)

Vedolizumab for the treatment of chronic pouchitis
著者:: Travis, S, 等
出版事項: (2023)

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
著者:: Renske W. M. Pauwels, 等
出版事項: (2020-12-01)

Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series
著者:: Suzanne I. Anjie, 等
出版事項: (2024-02-01)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
著者:: Matthew Luzentales-Simpson, 等
出版事項: (2021-02-01)

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
著者:: Pulusu, S, 等
出版事項: (2018)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
著者:: Kothari M, 等
出版事項: (2015-08-01)

Vedolizumab for inflammatory bowel diseasesI
著者:: Igor L. Khalif, 等
出版事項: (2018-08-01)

Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
著者:: A. O. Golovenko, 等
出版事項: (2018-10-01)

Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
著者:: Judy A. Trieu, 等
出版事項: (2017-12-01)

Vedolizumab-Induced Liver Injury
著者:: Miguel Mascarenhas Saraiva, 等
出版事項: (2020-12-01)

Vedolizumab in paediatric Inflammatory Bowel Disease: A retrospective multi-centre experience From the paediatric IBD Porto Group of ESPGHAN
著者:: Ledder, O, 等
出版事項: (2017)

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
著者:: Ledder, O, 等
出版事項: (2017)

Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis
著者:: Beatriz Gros, 等
出版事項: (2024-07-01)

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.
著者:: de Vries, E, 等
出版事項: (2016)

Vedolizumab in Inflammatory Bowel Disease: West versus East
著者:: Prasanta Debnath, 等
出版事項: (2021-01-01)

Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis
著者:: Martine Walmsley, 等
出版事項: (2024-06-01)

Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
著者:: Bhayat, F, 等
出版事項: (2017)

Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
著者:: Ledder, O, 等
出版事項: (2017)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
著者:: Feagan, B, 等
出版事項: (2017)

Clinical efficacy of vedolizumab for inflammatory bowel disease
著者:: Liu Sixue, Zhong Wa, Lin Ying, Xia Zhongsheng, Zhong Yingqiang
出版事項: (2022-10-01)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
著者:: Asaf Levartovsky, 等
出版事項: (2022-06-01)

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
著者:: Travis, S, 等
出版事項: (2018)

Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials
著者:: Feagan, BG, 等
出版事項: (2018)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
著者:: Abdulaziz Saad Alshahrani, 等
出版事項: (2023-09-01)

Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease
著者:: S. K. Zyryanov, 等
出版事項: (2018-05-01)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
著者:: Kira L. Newman, 等
出版事項: (2023-03-01)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
著者:: Merve Sivridaş, 等
出版事項: (2023-03-01)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
著者:: Fares Ayoub, 等
出版事項: (2022-04-01)

Introducing vedolizumab to clinical practice: who, when and how?
著者:: Bryant, R, 等
出版事項: (2015)

A product review of vedolizumab in inflammatory bowel disease
著者:: Robert Battat, 等
出版事項: (2019-10-01)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
著者:: Benjamin Crooks, 等
出版事項: (2020-03-01)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
著者:: Feagan, B, 等
出版事項: (2017)

Evaluating Efficacy of Vedolizumab, Ustekinumab, and Golimumab in the Management of Inflammatory Bowel Disease and the Combined Role of Nutritional Therapy with Biologics: A Review
著者:: Shahed Kamal, 等
出版事項: (2024-08-01)

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
著者:: Bhayat, F, 等
出版事項: (2017)

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
著者:: Bye, W, 等
出版事項: (2017)

Vedolizumab in Crohn Disease genesis-sefh drug evaluation report
著者:: Jenifer González Chávez, 等
出版事項: (2015-09-01)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease
著者:: Eddie Y. Liu, 等
出版事項: (2017-01-01)

Take vedolizumab home: transition from intravenous to subcutaneous treatment
著者:: Kaituo Huang, 等
出版事項: (2024-05-01)

Acquired hemophilia associated with vedolizumab in a patient with hemorrhagic rectocolitis
著者:: Thomas Schiestel
出版事項: (2023-03-01)